One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Jörg T. Hartmann, Daniel Pink, J. Schütte, Giuliano Ramadori, Peter Hohenberger, Justus Duyster, Salah‐Eddin Al‐Batran, M. Schlemmer, Sebastian Bauer, Eva Wardelmann, Maarit Sarlomo‐Rikala, Bengt Nilsson, Harri Sihto, Odd R. Monge, Petri Bono, Raija Kallio, Aki Vehtari, Mika Leinonen, Thor Alvegård, Peter Reichardt

JAMA, 2012

Helsinki University Hospital, University of Helsinki, Skåne University Hospital, University of Tübingen, Helios Hospital Berlin-Buch, Marien Hospital Düsseldorf, University of Göttingen, Heidelberg University, Heidelberg University, Technical University of Munich, Krankenhaus Nordwest, Ludwig-Maximilians-Universität München, University of Duisburg-Essen, University of Cologne, University of Gothenburg, University of Bergen, University of Oulu, Aalto University, Lund University

Publisher Website

Abstract

This research paper explore the methodology and findings associated with JAMA. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

961

Citations

View on Google Scholar

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

Abstract

Journal Details

Join JournalsHub

Welcome Back